A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

por Hajek, Roman, Pour, Ludek, Ozcan, Muhit, Martin Sánchez, Jesus, García Sanz, Ramon, Anagnostopoulos, Achilles, Oriol, Albert, Cascavilla, Nicola, Terjung, Andreas, Lee, Yihua, Briso, Eva M., Dobkowska, Edyta, Hauns, Bernhard, Špička, Ivan
Publicado 2020

Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

por Mateos, María Victoria, Prosper, Felipe, Martin Sánchez, Jesús, Ocio, Enrique M., Oriol, Albert, Motlló, Cristina, Michot, Jean‐Marie, Jarque, Isidro, Iglesias, Rebeca, Solé, María, Martínez, Sara, Kahatt, Carmen, Fudio, Salvador, Corral, Gema, Zeaiter, Ali, Montilla, Lola, Ribrag, Vincent
Publicado 2022

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

por Puig, Noemí, Corchete-Sánchez, Luis A., Pérez-Morán, José J., Dávila, Julio, Paíno, Teresa, de la Rubia, Javier, Oriol, Albert, Martín-Sánchez, Jesús, de Arriba, Felipe, Bladé, Joan, Blanchard, María-Jesús, González-Calle, Verónica, García-Sanz, Ramón, Paiva, Bruno, Lahuerta, Juan-José, San-Miguel, Jesús F., Mateos, María-Victoria, Ocio, Enrique M.
Publicado 2020